- Home
- LNKB vs NBTX Comparison
LNKB vs NBTX Comparison
Compare LNKB & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- NBTX
- Stock Information
- Founded
- LNKB 2018
- NBTX 2003
- Country
- LNKB United States
- NBTX France
- Employees
- LNKB N/A
- NBTX N/A
- Industry
- LNKB
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- NBTX Health Care
- Exchange
- LNKB Nasdaq
- NBTX Nasdaq
- Market Cap
- LNKB 236.7M
- NBTX 235.6M
- IPO Year
- LNKB N/A
- NBTX 2020
- Fundamental
- Price
- LNKB $6.25
- NBTX $5.05
- Analyst Decision
- LNKB Hold
- NBTX Strong Buy
- Analyst Count
- LNKB 1
- NBTX 2
- Target Price
- LNKB $7.50
- NBTX $11.50
- AVG Volume (30 Days)
- LNKB 45.7K
- NBTX 13.2K
- Earning Date
- LNKB 10-25-2024
- NBTX 10-15-2024
- Dividend Yield
- LNKB 4.79%
- NBTX N/A
- EPS Growth
- LNKB N/A
- NBTX N/A
- EPS
- LNKB N/A
- NBTX N/A
- Revenue
- LNKB $68,142,000.00
- NBTX $45,220,186.00
- Revenue This Year
- LNKB N/A
- NBTX N/A
- Revenue Next Year
- LNKB $4.03
- NBTX N/A
- P/E Ratio
- LNKB N/A
- NBTX N/A
- Revenue Growth
- LNKB 101.22
- NBTX 526.17
- 52 Week Low
- LNKB $5.86
- NBTX $4.14
- 52 Week High
- LNKB $8.29
- NBTX $8.96
- Technical
- Relative Strength Index (RSI)
- LNKB 45.31
- NBTX 47.92
- Support Level
- LNKB $6.17
- NBTX $4.93
- Resistance Level
- LNKB $6.46
- NBTX $5.36
- Average True Range (ATR)
- LNKB 0.15
- NBTX 0.36
- MACD
- LNKB -0.01
- NBTX -0.00
- Stochastic Oscillator
- LNKB 13.79
- NBTX 36.44
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.